CABG In Ischemic Cardiomyopathy: How Low Is Too Low and How Dead Is Too Dead?

All of the relevant financial relationships listed for these individuals have been mitigated. Unless otherwise noted, speakers have nothing to disclose.

Moderators

Joseph Cleveland, Jr., MD
Disclosure(s): Medtronic, Edwards, Boston Scientific, Abbott: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)

Leora Yarboro, MD
Disclosure(s): edwards: Speaker (Terminated, September 25, 2022)

Presentations

  1. Clinical Value of Pre-CABG Myocardial Viability Assessment by Magnetic Resonance Imaging in Patients with Ischemic Cardiomyopathy
    Brandon Peine, MD
     
  2. Effect of patent complete revascularization on the akinetic myocardial segments in preoperative echocardiography
    Min-Seok Kim, MD, PhD, MSc
     
  3. Should multiarterial grafting be the standard of care for ischemic cardiomyopathy patients undergoing coronary artery bypass grafting?
    Dror B. Leviner, MD
     
  4. Invited Discussant
    Marisa Cevasco, MD
    Disclosure(s): Abiomed: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)
     
  5. Who and What to Bypass in Ischemic Cardiomyopathy
    Edwin C. McGee, Jr., MD
     
  6. IMPACT: Implications on Cardiac Surgery in Patients with Ischemic Cardiomyopathy
    Daniel Goldstein, MD
    Disclosure(s): Abbott Inc.: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Abiomed Inc.: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Vascular Graft Solutions Inc: Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)
     
  7. Case Presentation: 60M EF 25-30%, mild MR, HTN, DM, non-transplant center
    Leora Yarboro, MD
    Disclosure(s): edwards: Speaker (Terminated, September 25, 2022)
     
  8. Panel Discussion and Audience Q&A
Activity summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit
  • 1.50 Participation
Activity opens: 
02/01/2024
Activity expires: 
02/15/2027
Cost:
$0.00
Rating: 
5

Available Credit

  • 1.50 AMA PRA Category 1 Credit
  • 1.50 Participation

Price

Cost:
$0.00
Please login or register to take this course.

All of the relevant financial relationships listed for these individuals have been mitigated. Unless otherwise noted, speakers have nothing to disclose.

Moderators

Joseph Cleveland, Jr., MD
Disclosure(s): Medtronic, Edwards, Boston Scientific, Abbott: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)

Leora Yarboro, MD
Disclosure(s): edwards: Speaker (Terminated, September 25, 2022)

Presentations

  1. Clinical Value of Pre-CABG Myocardial Viability Assessment by Magnetic Resonance Imaging in Patients with Ischemic Cardiomyopathy
    Brandon Peine, MD
     
  2. Effect of patent complete revascularization on the akinetic myocardial segments in preoperative echocardiography
    Min-Seok Kim, MD, PhD, MSc
     
  3. Should multiarterial grafting be the standard of care for ischemic cardiomyopathy patients undergoing coronary artery bypass grafting?
    Dror B. Leviner, MD
     
  4. Invited Discussant
    Marisa Cevasco, MD
    Disclosure(s): Abiomed: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)
     
  5. Who and What to Bypass in Ischemic Cardiomyopathy
    Edwin C. McGee, Jr., MD
     
  6. IMPACT: Implications on Cardiac Surgery in Patients with Ischemic Cardiomyopathy
    Daniel Goldstein, MD
    Disclosure(s): Abbott Inc.: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Abiomed Inc.: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Vascular Graft Solutions Inc: Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)
     
  7. Case Presentation: 60M EF 25-30%, mild MR, HTN, DM, non-transplant center
    Leora Yarboro, MD
    Disclosure(s): edwards: Speaker (Terminated, September 25, 2022)
     
  8. Panel Discussion and Audience Q&A